Science & Technology
Science and Technology
Science and Technology
Tue, April 12, 2011
iCAD Granted U.S. Patent on MRI Image Analysis Solutions
NASHUA, N.H.--([ BUSINESS WIRE ])--iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, announces that the United States Patent and Trademark Office recently granted the company Patent Number 7,903,853. This patent covers iCADa™s sophisticated magnetic resonance imaging (MRI) analysis products for breast and prostate cancer detection, and relates to the speed its image analysis solution pinpoints and marks areas that warrant closer inspection from a radiologist. iCADa™s VividLooka", SpectraLooka" and OmniLooka", utilize this technology to offer a comprehensive quantitative image analysis suite for cancer detection, localization, staging, treatment planning and serial monitoring.
aAs MRI imaging becomes more widely used for breast and prostate cancer detection, the number of images radiologists have to review is ever increasing. iCADa™s research and development teams are continuing to develop and protect new image analysis breakthroughs that meet the needs of our global customers by helping detect more cancers at an earlier stage from among the hundreds of images generated in these exams,a said Ken Ferry, President and CEO of iCAD.
This patent is included among iCADa™s broad patent portfolio that is based on years of research and development on solutions for existing and new product applications. iCAD currently has 57 granted U.S. patents, 28 U.S. patent applications and 23 foreign patent applications.
iCADa™s SpectraLook breast MRI image analysis solution provides more diagnostic information by encompassing all available time points of the MRI dataset creating colorized images based on signal changes defined by tumor physiology. This unique technology is designed to assist radiologists in distinguishing potential cancers in the breast as part of their overall analysis of MRI studies. When coupled with VersaVue EnterpriseTM, iCADa™s image review and analysis software, this comprehensive solution improves the analysis workflow, interventional planning and reporting of breast MRI results while streamlining the radiologista™s workflow and diagnosis.
VividLook, iCADa™s quantitative image analysis solution for prostate MRI, is a post processing software package designed to help radiologists distinguish benign from malignant lesions by providing a reliable means of visualizing the presence and pattern of contrast-induced enhancement of MRI images of the prostate. The solution provides more diagnostic information by utilizing all available time points of the MRI imaging protocol and creates colorized images based on signal changes defined by tumor physiology. In addition, VividLook can provide better localization capability for biopsy thereby increasing specificity.
This advanced MRI product suite was launched in August of 2010 and is available worldwide.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography, Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). iCAD recently acquired Xoft, Inc., developer of the Axxent® eBxa" electronic brachytherapy system (eBx). Axxent uses non-radioactive miniaturized X-ray tube technology and is FDA-cleared for treatment of early stage breast cancer, skin cancer and endometrial cancer. The Axxent System is also cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated including Intraoperative Radiation Therapy (IORT). For more information, call (877) iCADnow or visit [ www.icadmed.com ].
**NOTE TO EDITORS, IMAGES AVAILABLE
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute aforward-looking statementsa within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Companya™s filings with the Securities and Exchange Commission. The words abelievea, ademonstratea, aintenda, aexpecta, aestimatea, aanticipatea, alikelya, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
